{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
progesterone
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Tanaproget (WAY-166989) is a nonsteroidal progesterone receptor agonist. It has been in Phase-II clinical trials as an oral contraceptive. The compound demonstrated a positive preclinical pharmacological profile in the treatment of endometriosis. The level of progesterone receptors in breast tumours can be used to guide the selection of endocrine therapies for breast cancer patients. Radiolabeled analogues of tanaproget have diagnostic potential as PET imaging agents for breast cancer.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Aglepristone (RU 46534) is a competitive progesterone antagonist; it binds to progesterone receptors (PRs) without inducing the molecular cascade associated with progesterone. Its affinity to PRs is higher than progesterone (3.12, 3.8, and 9.26 times greater in the bitch, doe rabbit,and queen, respectively). Aglepristone can therefore beused in various progesterone-dependent physiological orpathologic conditions, with the aim of blocking the action of progesterone. Aglepristone has proven to be an effective and safe means of inducing pregnancy termination or parturition in a large number of domestic species. In domestic species, aglepristone is routinely used for the treatment of pyometra and feline mammary fibroadenomatous hyperplasia, both of which are progesterone dependent. Aglepristone is marketed under the brand name Alizin used as the treatment option for unwanted mating and pregnancy in dogs
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Lonaprisan is an orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist (both PR isoforms PR-A and PR-B); binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Lonaprisan showed limited efficacy as second-line endocrine therapy in postmenopausal women with PR-positive metastatic breast cancer. Lonaprisan had been in phase II clinical trials by Bayer for the treatment of breast cancer and dysmenorrhea. However, this research has been discontinued.
Status:
Investigational
Source:
INN:lilopristone [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Lilopristone (ZK 98.734) has a high affinity for progesterone receptors. The progesterone antagonistic effects of ZK 98.734 could be a result of the decrease in progesterone synthesis by the corpus luteum and/or placenta in addition to the interference with the progesterone binding to its cellular receptors in the target organ. ZK 98.734 has potential for fertility regulation. It is a very potent abortifacient in the common marmosets. Lilopristone could significantly suppress the proliferation of ectopic stromal cells in a time- and dose-dependent manner in vitro. The action mechanisms may be associated with the suppression of expression of NF-kappaB P65 mRNA and NF-kappaB P65.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Asoprisnil (J867) is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. Asoprisnil, its major metabolite J912, and other structurally related compounds represent a new class of progesterone receptor (PR) ligands that exhibit partial agonist and antagonist activities in vivo. Asoprisnil demonstrates a high degree of receptor and tissue selectivity, with a high-binding affinity for PR, moderate affinity for glucocorticoid receptor (GR), low affinity for androgen receptor (AR), and no binding affinity for estrogen or mineralocorticoid receptors. This compound was recently in clinical trials for the treatment of uterine fibroids and endometriosis, but those studies were discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Epostane (WIN-32729) a pure competitive inhibitor of 3-beta-hydroxysteroid dehydrogenase. Epostane blocks progesterone synthesis during the luteal phase and in pregnancy in women and has strong anti-steroidogenic effect in endocrine tissues. Epostane is an abortifacient agent in early human pregnancy. It inhibits ovarian follicular steroidogenesis and ovulation.
![Structure of Potassium [[(3E)-20-oxopregn-4-en-3-ylidene]amino]oxy]acetic acid](/img/76b7438e-2970-4cb0-8c44-5d8cfa4d8a4d.svg?size=200&context=fhmvzuuuzf)